BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Advances Development of ClearMetrX 4.0 With AI-Enhanced Healthcare Analytics

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company, announced its ClearMetrx subsidiary has entered late-stage development of ClearMetrX 4.0, the next generation of its proprietary healthcare data analytics and reporting software. Scheduled for internal rollout in Q4 2025 and commercialization in the first half of 2026, ClearMetrX 4.0 integrates AI-powered capabilities including revenue forecasting, predictive inventory management, anomaly detection, fraud prevention, audit support, and scenario modeling. The cloud-based platform is already in use across the Company’s pharmacies and client network, streamlining analytics for physicians, MSOs, 340B entities, and pharmacies. NextPlat said the upgrade reflects its commitment to improving healthcare efficiency, compliance, and patient outcomes as global demand for AI-driven healthcare solutions accelerates.

To view the full press release, visit: https://ibn.fm/yoQEU

About NextPlat Corp

Nextplat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN